Neuropathy

Early prevention of neuropathic pain

An unpleasant tingling in the hands and feet, numbness, furry and burning sensations – these symptoms may indicate a neuropathy, a disease of the nervous system. If the pain persists for several months, it is referred to as chronic pain. By then, it is very difficult to treat, and the available drugs often have serious side effects. Researchers at the Translational Medicine and Pharmacology TMP branch of the Fraunhofer Institute for Molecular Biology and Applied Ecology IME have found a way to prevent the development of neuropathic pain early on.

Around five million people in Germany suffer from neuropathic pain, which is the result of damage to the peripheral or central nervous system. Its causes are numerous and diverse. Neuropathic pain can occur after an operation, such as bypass surgery, or an accident, for instance when the spinal cord has been injured. Also phantom pain, which many patients experience following an amputation, is also a neuropathic, mechanically induced pain. A change in skin sensitivity is typical for neuropathic pain. Stimuli such as cold, heat or touches are felt more intensely or hardly at all. The situation becomes problematic when the pain takes on a life of its own and becomes chronic, as this has a major adverse effect on the patients’ quality of life. They can often no longer practice their profession, and they neglect their friendships and leisure activities. As a result, they become isolated, resigned and depressed.

The development of neuropathic, trauma-induced pain that often occurs following an operation or accident should be prevented at as early a stage as possible, because once neuropathic pain has developed, treatment has only a limited effect – and the relevant drugs have strong side effects.

When immune cells become the enemy

This is where the researchers at the Frankfurt-based Fraunhofer IME began their approach. They are researching alternative therapies for the early treatment of neuropathic pain. They conducted tests in which they were able to show that various lipids that act as signaling molecules and are produced when an injury occurs control the inflammatory responses in the damaged nerves. “The nerves sound the alarm and release lipids to signal to the immune system that an injury has occurred and the cause must be eliminated,” says Prof. Klaus Scholich, group manager for biomedical analytics and imaging at Fraunhofer IME. “In the case of neuropathic pain, the immune cells that were lured to the site of the injury soon become the enemy, interacting with the
nerves in a way that results in permanent inflammation in the affected areas. The neuropathic pain can no longer subside and becomes chronic. We can significantly reduce the pain by blocking signaling pathways that attract immune cells.” One way to do this is by using painkillers such as ibuprofen and diclofenac. Administered at an early stage, these drugs can stop the production of prostaglandin E2, a lipid that plays a key role in trauma-induced pain because it both sensitizes the nerves and activates the immune system.

Prostaglandin E2 also binds the EP3 receptor. Neurons that express this receptor produce the signaling molecule CCL2, which in turn contributes significantly to pain development because it constantly lures new immune cells to the injured nerves and, as the IME researchers discovered in their studies, is itself involved in amplifying pain perception. “We were able to shed light on the subsequent mechanisms that promote the genesis of neuropathic pain by means of inflammatory responses,” explains Prof. Scholich. “The EP3 receptor recognizes the prostaglandin E2. By switching off the EP3, thus inhibiting CCL2 release, pain genesis can now be significantly reduced.” The CCL2 could be intercepted with specific therapeutic antibodies, which are used for chronic pain when conventional drugs such as ibuprofen no longer work. The disadvantage of this approach is that antibodies have to be injected. Since most patients find this unpleasant, Scholich and his colleagues are researching alternative agents that can be administered orally. The researchers published their findings in the prestigious Journal of Biological Chemistry.
The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 72 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 26,600, who work with an annual research budget totaling 2.6 billion euros. Of this sum, 2.2 billion euros is generated through contract research. Around 70 percent of the Fraunhofer-Gesellschaft’s contract research revenue is derived from contracts with industry and from publicly financed research projects.

International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.